Cannara Biotech Inc., a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., has announced its fiscal first quarter 2023 financial and operating results for the three-month period ended November 30, 2022. The company recorded $10.3 million in quarterly revenue; a 57% increase compared to Q1 2022. Cannara Biotech has also delivered its seventh consecutive quarter of positive Adjusted EBITDA of $1.7M and reported positive net income for a second consecutive quarter. There is a continued to increase growing capacity to meet customer demand by activating new growing zone in its expanding Valleyfield Facility.

Cannara Biotech Inc. is a Bristol Investor Relations client.

Read the full press release here: Cannara Biotech Inc. Reports Q1 2023 Financial Results